Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion

Molecular Biology of the Cell

Volumn 25, Issue 16, 2014, Pages 2320-2332

  Elderbroom, Jennifer L ^a   Huang, Jennifer J ^a   Gatza, Catherine E ^a   Chen, Jian ^a   How, Tam ^a   Starr, Mark ^a   Nixon, Andrew B ^a   Blobe, Gerard C ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUTANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; PROTEOGLYCAN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; BREAST METASTASIS; CANCER GROWTH; CELL MIGRATION; CONTROLLED STUDY; COS 7 CELL LINE; CYTOKINE PRODUCTION; ECTODOMAIN SHEDDING; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFANT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; BREAST TUMOR; CELL MOTION; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, NUDE; MUTATION; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA3;

EID: 84905983197     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E13-09-0524     Document Type: Article

References (46)

1. Andres JL, DeFalcis D, Noda M, Massague J (1992). Binding of two growth factor families to separate domains of the proteoglycan betaglycan. J Biol Chem 267, 5927-5930.
2. Arribas J, Borroto A (2002). Protein ectodomain shedding. Chem Rev 102, 4627-4638.
3. Arribas J, Lopez-Casillas F, Massague J (1997). Role of the juxtamembrane domains of the transforming growth factor-alpha precursor and the beta-amyloid precursor protein in regulated ectodomain shedding. J Biol Chem 272, 17160-17165. (Pubitemid 27289827)
4. Bandyopadhyay A, Lopez-Casillas F, Malik SN (2002). Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res 63, 4690-4695.
5. Bandyopadhyay A, Zhu Y, Cibull LB (1999). A soluble transforming growth factor b type III receptor suppresses tumorigenicity and metastasis of human breast MDA-MB-231 cells. Cancer Res 59, 5041-5046. (Pubitemid 29472913)
6. Bernabeu C, Lopez-Novoa JM, Quintanilla M (2009). The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta 1792, 954-973.
7. Blair CR, Stone JB, Wells RG (2011). The type III TGF-beta receptor betaglycan transmembrane-cytoplasmic domain fragment is stable after ectodomain cleavage and is a substrate of the intramembrane protease gamma-secretase. Biochim Biophys Acta 1813, 332-339.
8. Blobe GC, Liu X, Fang SJ, How T, Lodish HF (2001). A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC. J Biol Chem 276, 39608-39617.
9. Cheifetz S, Hernandez H, Laiho M, ten Dijke P, Iwata KK, Massague J (1990). Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms. J Biol Chem 265, 20533-20538. (Pubitemid 120014040)
10. Chen W, Kirkbride KC, How T, Nelson CD, Mo J, Frederick JP, Wang XF, Lefkowitz RJ, Blobe GC (2003). Beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling. Science 301, 1394-1397. (Pubitemid 37075818)
11. Connolly EC, Freimuth J, Akhurst RJ (2012). Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci 8, 964-978.
12. Criswell TL, Dumont N, Barnett JV, Arteaga CL (2008). Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells. Cancer Res 68, 7304-7312.
13. De Crescenzo G et al. (2006). Three key residues underlie the differential affinity of the TGFbeta isoforms for the TGFbeta type II receptor. J Mol Biol 355, 47-62. (Pubitemid 41774138)
14. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC (2007). The type III TGF-beta receptor suppresses breast cancer progression. J Clin Invest 117, 206-217. (Pubitemid 46048467)
15. Elliott RL, Blobe GC (2005). Role of transforming growth factor beta in human cancer. J Clin Oncol 23, 2078-2093. (Pubitemid 46211385)
16. Finger EC, Turley RS, Dong M, How T, Fields TA, Blobe GC (2008). TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis 29, 528-535. (Pubitemid 351404868)
17. Gatza CE, Elderbroom JE, Oh SY, Starr M, Nixon A, Blobe GC (2014). The balance of cell surface and soluble type III TGFbeta receptor regulates BMP signaling in normal and cancerous mammary epithelial cells. Neoplasia 16, 489-500.
18. Ghellal A, Li C, Hayes M, Byrne G, Bundred N, Kumar S (2000). Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma. Anticancer Res 20, 4413-4418. (Pubitemid 32141796)
19. Hamad NM, Banik SS, Counter CM (2002). Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells. Oncogene 21, 7121-7125. (Pubitemid 35252986)
20. Hanks BA et al. (2013). Type III TGF-beta receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest 123, 3925-3940.
21. Killock DJ, Ivetic A (2010). The cytoplasmic domains of TNFalpha-converting enzyme (TACE/ADAM17) and L-selectin are regulated differently by p38 MAPK and PKC to promote ectodomain shedding. Biochem J 428, 293-304.
22. Kirkbride KC, Townsend TA, Bruinsma MW, Barnett JV, Blobe GC (2008). Bone morphogenetic proteins signal through the transforming growth factor-beta type III receptor. J Biol Chem 283, 7628-7637.
23. Lambert KE, Huang H, Mythreye K, Blobe GC (2011). The type III transforming growth factor-beta receptor inhibits proliferation, migration, adhesion in human myeloma cells. Mol Biol Cell 22, 1463-1472.
24. Lei X, Bandyopadhyay A, Le T, Sun L (2002). Autocrine TGFbeta supports growth and survival of human breast cancer MDA-MB-231 cells. Oncogene 21, 7514-7523. (Pubitemid 35305579)
25. Lewis KA, Gray PC, Blount AL, Mac Conell LA, Wiater E, Bilezikjian LM, Vale W (2000). Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 404, 411-414. (Pubitemid 30164345)
26. Liu C, Xu P, Lamouille S, Xu J, Derynck R (2009). TACE-mediated ectodomain shedding of the type I TGF-beta receptor downregulates TGF-beta signaling. Mol Cell 35, 26-36.
27. Lopez-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS, Massague J (1991). Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system. Cell 67, 785-795. (Pubitemid 121001491)
28. Lopez-Casillas F, Payne HM, Andres JL, Massague J (1994). Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol 124, 557-568. (Pubitemid 24064466)
29. Lopez-Casillas F, Wrana JL, Massague J (1993). Betaglycan presents ligand to the TGF beta signaling receptor. Cell 73, 1435-1444. (Pubitemid 23201155)
30. Massague J (2008). TGFbeta in cancer. Cell 134, 215-230.
31. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J (2005). Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524. (Pubitemid 41112921)
32. Mooradian DL, McCarthy JB, Komanduri KV, Furcht LT (1992). Effects of transforming growth factor-beta 1 on human pulmonary adenocarcinoma cell adhesion, motility, and invasion in vitro. J Natl Cancer Inst 84, 523-527.
33. Mu Y et al. (2011). TRAF6 ubiquitinates TGFbeta type I receptor to promote its cleavage and nuclear translocation in cancer. Nat Commun 2, 330.
34. Mythreye K, Blobe GC (2009). The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci USA 106, 8221-8226.
35. Perez-Torres M, Valle BL, Maihle NJ, Negron-Vega L, Nieves-Alicea R, Cora EM (2008). Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells. Exp Cell Res 314, 2907-2918.
36. Riggins GJ, Kinzler KW, Vogelstein B, Thiagalingam S (1997). Frequency of Smad gene mutations in human cancers. Cancer Res 57, 2578-2580. (Pubitemid 27283760)
37. Seo M, Lee MJ, Heo JH, Lee YI, Kim Y, Kim SY, Lee ES, Juhnn YS (2007). G Protein betagamma subunits augment UVB-induced apoptosis by stimulating the release of soluble heparin-binding epidermal growth factor from human keratinocytes. J Biol Chem 282, 24720-24730. (Pubitemid 47347554)
38. Siegel PM, Massague J (2003). Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3, 807-821.
39. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin 62, 10-29.
40. Song J, Tan H, Perry AJ, Akutsu T, Webb GI, Whisstock JC, Pike RN (2012). PROSPER: an integrated feature-based tool for predicting protease substrate cleavage sites. PLoS One 7, e50300.
41. Sun L, Chen C (1997). Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J Biol Chem 272, 25367-25372. (Pubitemid 27415730)
42. Teixido J, Wong ST, Lee DC, Massague J (1990). Generation of transforming growth factor-alpha from the cell surface by an O-glycosylation-independent multistep process. J Biol Chem 265, 6410-6415.
43. Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC (2007). The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res 67, 1090-1098.
44. Velasco-Loyden G, Arribas J, Lopez-Casillas F (2004). The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1. J Biol Chem 279, 7721-7733. (Pubitemid 38294655)
45. Verona EV, Tang Y, Millstead TK, Hinck AP, Agyin JK, Sun L-Z (2008). Expression, purification and characterization of BGERII: a novel pan-TGFβ inhibitor. Protein Eng Des Sel 21, 463-473. (Pubitemid 351882136)
46. Wang XF, Lin HY, Ng-Eaton E, Downward J, Lodish HF, Weinberg RA (1991). Expression cloning and characterization of the TGF-beta type III receptor. Cell 67, 797-805. (Pubitemid 121001492)